{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:17:35Z","timestamp":1789690655091,"version":"4.0.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a lack of benefit\/harm assessments of illicit and licit psychoactive substances performed by substance-dependent users in comparison to addiction medicine experts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We extended the analyses of substance harm\/benefit assessments of German addiction medicine experts (\n                      <jats:italic>N<\/jats:italic>\n                      = 101), in parts reported recently in this journal [\n                      <jats:ext-link>doi.org\/10.3389\/fpsyt.2020.59219<\/jats:ext-link>\n                      ], by the perspectives of substance-addicted persons. The same questionnaire as used for the abovementioned \u201cexperts-study\u201d was handed out to inpatient detoxification or rehab treatment seeking German substance-dependent adults (\n                      <jats:italic>N<\/jats:italic>\n                      = 117) for a subsequent structured interview about harms and benefits of 33 new and traditional psychoactive substances comprising also prescription drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>Both, users and experts, ranked the traditional illicit psychoactive substances heroin, cocaine and amphetamines within the top overall harm level group. Synthetic cannabinoids, alcohol and benzodiazepine were in a subordinate top-harm level position. Both cohorts also ranked methadone, nicotine and cannabis within the midrange and buprenorphine as well as psychotropic mushrooms within the lowest harm level positions. Experiences with prescription drugs (including opioidergic analgesics and gabapentinoids), cathinones, GHB, methamphetamine and methylphenidate was not prevalent in our user population. The same applied to barbiturates, propofol, kratom, ayahuasca with nearly zero assessments for each substance. The most user-experiences (&amp;gt;50% per assessed substance) were reported with nicotine, cannabis, alcohol, cocaine, heroin, amphetamine and methadone (core group). The user\u2019s overall harm ratings in terms of these psychoactive substances were similar to those of the experts with the exception of the methadone assessment which was rated by the experts to be significantly less harmful if compared with the users\u2019 estimation (supposed \u201ctreatment bias\u201d of experts). The users\u2019 benefit ratings for the traditional illicit psychoactive substances, cannabis as well as for nicotine were significantly more positive in comparison to those of the experts (supposed \u201cattraction bias\u201d of users). Both, experts and users, ranked the harms arising from the use of alcohol or benzodiazepines (usually unregulated substances) higher than the harms caused by the use of methadone, cannabis or psychotropic mushrooms (regulated by most Western narcotic acts). Users attributed the most benefits to buprenorphine, methadone and cannabis. This might reflect a main limitation of the study as the data are from an user population comprising over 50% patients who sought detoxification-treatment of opiates where methadone and buprenorphine are usual transient medications (supposed \u201cselection bias\u201d).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study addressed current trends of psychoactive substance abuse (e.g., synthetic cannabinoids, prescription drugs) and provides from both perspectives (that of the user and that of the addiction medicine experts) robust harm\/benefit evaluations at least of a core group of psychoactive substances (traditional illicit psychoactive substances, cannabis, methadone, alcohol and nicotine). The results of this study can be valuable to the psychoeducation of substance-addicted individuals and to current restriction\/legalization debates, especially in the Western-EU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2022.1041762","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T02:12:32Z","timestamp":1668564752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Differences between users\u2019 and addiction medicine experts\u2019 harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization\/restriction debates"],"prefix":"10.3389","volume":"13","author":[{"given":"Udo","family":"Bonnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Specka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kristin","family":"Kanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Scherbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"592199","DOI":"10.3389\/fpsyt.2020.592199","article-title":"Ranking the harm of psychoactive drugs including prescription analgesics to users and others-a perspective of german addiction medicine experts.","volume":"11","author":"Bonnet","year":"2020","journal-title":"Front Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000324065","article-title":"Addiction and brain reward and antireward pathways.","volume":"30","author":"Gardner","year":"2011","journal-title":"Adv Psychosom Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1124\/pr.115","article-title":"Mechanisms of action and persistent neuroplasticity by drugs of abuse.","volume":"67","author":"Korpi","year":"2015","journal-title":"Pharmacol Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41386-020-00950-y","article-title":"Addiction as a brain disease revised: why it still matters, and the need for consilience.","volume":"46","author":"Heilig","year":"2021","journal-title":"Neuropsychopharmacology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"15037","DOI":"10.1073\/pnas.1010654108","article-title":"Addiction: beyond dopamine reward circuitry.","volume":"108","author":"Volkow","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis.","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000317249","article-title":"Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population.","volume":"16","author":"van Amsterdam","year":"2010","journal-title":"Eur Addict Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0269881115581980","article-title":"European rating of drug harms.","volume":"29","author":"van Amsterdam","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1360-0443.2011.03675.x","article-title":"A damage\/benefit evaluation of addictive product use.","volume":"107","author":"Bourgain","year":"2012","journal-title":"Addiction."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e000774","DOI":"10.1136\/bmjopen-2011-000774","article-title":"Quantifying the RR of harm to self and others from substance misuse: results froma survey of clinical experts across Scotland.","volume":"2","author":"Taylor","year":"2012","journal-title":"BMJ Open."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8126","DOI":"10.1038\/srep08126","article-title":"Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach.","volume":"5","author":"Lachenmeier","year":"2015","journal-title":"Sci Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/0269881119841569","article-title":"The Australian drug harms ranking study.","volume":"33","author":"Bonomo","year":"2019","journal-title":"J Psychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.yrtph.2015.09.014","article-title":"Ranking the harm of non-medically used prescription opioids in the UK.","volume":"73","author":"van Amsterdam","year":"2015","journal-title":"Regul Toxicol Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/a-1363-0223","article-title":"[Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts].","volume":"90","author":"Bonnet","year":"2022","journal-title":"Fortschr Neurol Psychiatr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/0269881113477744","article-title":"Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.","volume":"27","author":"Morgan","year":"2013","journal-title":"J Psychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1177\/0269881113487809","article-title":"Quantitative damage-benefit evaluation of drug effects: major discrepancies between the general population, users and experts.","volume":"27","author":"Reynaud","year":"2013","journal-title":"J Psychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0034-1399307","article-title":"[Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard].","volume":"83","author":"Bonnet","year":"2015","journal-title":"Fortschr Neurol Psychiatr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1055\/s-0043-102059","article-title":"New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.","volume":"50","author":"Scherbaum","year":"2017","journal-title":"Pharmacopsychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review.","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur Neuropsychopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.addbeh.2018.11.009","article-title":"Screening for physical and behavioral dependence on non-opioid analgesics in a German elderly hospital population.","volume":"90","author":"Bonnet","year":"2019","journal-title":"Addict Behav."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.20882\/adicciones.1694","article-title":"Impact of the legalisation of recreational cannabis use.","author":"Isorna","year":"2022","journal-title":"Adicciones."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s15016-022-9491-8","article-title":"Positionspapier der DGPPN. Cannabis-Legalisierung: Pr\u00e4vention und Jugendschutz sind nicht verhandelbar.","volume":"33","author":"Wodarz","year":"2022","journal-title":"NeuroTransmitter."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(19)31082-7","article-title":"Denver votes to decriminalise psilocybin mushrooms.","volume":"393","author":"Webster","year":"2019","journal-title":"Lancet."},{"key":"B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2022.2050858","article-title":"The role of gabapentinoids in the substance use pattern of adult germans seeking inpatient detoxification treatment - a pilot study.","author":"Bonnet","year":"2022","journal-title":"J Psychoact Drugs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"100309","DOI":"10.1016\/j.lana.2022.100309","article-title":"Gabapentinoid-related deaths: An alarming global trend or just a special challenge within the long tail of the giant opioid epidemic?","volume":"11","author":"Bonnet","year":"2022","journal-title":"Lancet Reg Health \u2013 Am."},{"key":"B26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/YCO.0000000000000712","article-title":"The opioid overdose crisis as a global health challenge.","volume":"34","author":"Krausz","year":"2021","journal-title":"Curr Opin Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/ejp.1786","article-title":"Is Europe also facing an opioid crisis?-A survey of European Pain Federation chapters.","volume":"25","author":"H\u00e4user","year":"2021","journal-title":"Eur J Pain."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","article-title":"Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.","volume":"18","author":"Dematteis","year":"2017","journal-title":"Expert Opin Pharmacother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1037\/0033-2909.132.3.443","article-title":"The addiction-stroop test: Theoretical considerations and procedural recommendations.","volume":"132","author":"Cox","year":"2006","journal-title":"Psychol Bull."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/mpr.246","article-title":"Why people change? The role of cognitive-control processes in the onset and cessation of substance abuse disorders.","author":"B\u00fchringer","year":"2008","journal-title":"Int J Methods Psychiatr Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1037\/amp0000059","article-title":"Liking, wanting, and the incentive-sensitization theory of addiction.","volume":"71","author":"Berridge","year":"2016","journal-title":"Am Psychol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.addbeh.2014.10.005","article-title":"Less than meets the eye: reappraising the clinical relevance of attentional bias in addiction.","volume":"44","author":"Christiansen","year":"2015","journal-title":"Addict Behav."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1041762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T02:12:37Z","timestamp":1668564757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1041762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":32,"alternative-id":["10.3389\/fpsyt.2022.1041762"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1041762","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"article-number":"1041762"}}